Factsheet

Price & NAV Data

As at 31 Oct 2022

Price

1215.00p

NAV

1314.98p

Premium (+) / Discount (-)

-7.6%

OCF to 30.06.22

1.3%

Standing Data

As at 31 Oct 2022

Portfolio Manager post 31.5.19

Michael O'Brien

Fund Type

Investment Trust

EPIC Code/Ticker

FEET

Inception Date

25th June 2014

Performance Fee

None

AMC pre/post 31.5.19

1.25% / 1.0%

Base Currency

GBP

Sponsor & Broker

Investec Bank

Legal Adviser

Travers Smith LLP

Auditor

Deloitte LLP

Administrator

Northern Trust

Registrar

Link Asset Services

Depositary

Northern Trust

Co. Secretary

Frostrow Capital LLP

Dealing

LSE Main Market

AIC Sector

Emerging Markets

Key Facts

As at 31 Oct 2022 by Listing

Est Portfolio Yield^

1.6%

No. Holdings

30

Median Company Founded

1984

Median Market Cap

£8.5bn

Gearing policy

None

No. Shares in Issue

26,288,283

Market Capitalisation

£319m

2021 Transaction Costs

0.06%

2021 PTR*

38.0%

Geographical Split

As at 31 Oct 2022 by Listing

%

India

42.6

US

17.1

Hong Kong

5.9

Brazil

4.2

China

4.1

Other Countries

10.9

Cash incl. Money Market a/c's

15.2

Sector Split

As at 31 Oct 2022 by NAV - GICS® Categories

%

Consumer Staples

38.0

Technology

13.9

Communication Services

9.3

Healthcare

8.1

Materials

5.6

Consumer Discretionary

5.5

Industrials

2.6

Financials

1.9

Cash incl. Money Market a/c's

15.2

Security Identification Codes

Name

Code

SEDOL

BLSNND1

ISIN

GB00BLSNND18

EPIC

FEET

IMPORTANT NOTE

The Board of Fundsmith Emerging Equities Trust plc ('the Company') announced on 14th September 2022 that, following notification from Fundsmith LLP (the investment manager and AIFM of the Company) that it intends to give notice under the investment management agreement, proposals will be put forward for the Company to be placed into voluntary liquidation, with the cash proceeds arising on realisation of the portfolio returned to shareholders. Until the appointment of the liquidator FEET shares remain tradeable on the London Stock Exchange.

Further information can be found here; https://www.feetplc.co.uk/news/feet-news/?id=ry5z09w. Should you require further guidance on what this means please contact a suitably qualified financial adviser.

Fund Aim

To provide shareholders with an attractive return by investing in a portfolio of shares issued by listed or traded companies which have the majority of their operations in, or revenue derived from, Developing Economies and which provide direct exposure to the rise of the consumer classes in those countries or to the broader social and/or economic development of those countries.

The Company maintains a portfolio diversified by issuer concentration and the Company's portfolio will normally comprise 25 to 40 investments.

The Investment Manager intends to find companies which make their money by a large number of everyday, repeat, relatively predictable transactions. Its strategy is to not overpay when buying the shares of such companies and then do as little dealing as possible in order to minimise the expenses of the Company, allowing the investee companies' returns to compound for Shareholders with minimum interference.

The Investment Manager will avoid the financial sector and heavily cyclical sectors such as construction and manufacturing, utilities, resources and transport, and will instead focus almost exclusively on consumer stocks and in any event only on stocks in companies which will benefit from the rise of the consuming class in the Developing Economies.

The companies in which the Company will seek to invest have relatively predictable revenues and low capital intensity, and correspondingly high returns on capital. The targeted companies will also deliver most or all of their profits in cash. They will have defensible and strong market positions, typically derived from a combination of brands, trademarks and distribution systems or networks. The Investment Manager believes this combination will deliver compound growth in shareholder value over the long term.

The Investment Manager is also cognisant of the additional risks of investing in Developing Economies as opposed to developed economies, both in terms of the countries in which the companies operate and the standard of corporate governance within the companies themselves. The Investment Manager will take into account the degree of economic freedom, particularly the measure derived by the Heritage Foundation, of the country in which the companies are listed and/or operate in assessing the risks of any particular opportunity.

Past performance is not a guide to future performance.

Performance Overview, % Return

Oct

2022 to

2021

2020

2019

2018

2017

Inception to

Annualised to

2022

31.10.22

31.10.22

31.10.22

FEET NAV1

-5.4

-13.1

+3.8

+20

.7

-0

.5

-3.0

+21.2

+32.9

+3.5

FEET Share Price

-9.3

-11.0

-3.4

+29.1

-7.4

-9.4

+24.5

+22.3

+2.4

Equities2

-6.1

-17.0

-1.4

+14.4

+13.9

-9.3

+25.3

+45.1

+4.6

UK Bonds3

+4.5

-15.2

-4.5

+4.6

+3.8

+1.2

+1.4

+4.3

+0.5

Cash4

+0.2

+0.9

+0.1

+0

.3

+0

.8

+0.7

+0.4

+4.6

+0.5

1Source: Bloomberg, starting NAV 995.5, net of fees. 2MSCI Emerging & Frontier Markets Index, £ Net, source: www.msci.com.

3Bloomberg/Barclays Bond Indices UK Govt 5-10yr, source: Bloomberg. 4 £ Interest Rate, source: Bloomberg.

Portfolio Comment for October 2022

We began buying a new position for the fund, the name of which will be revealed when we have accumulated our desired weighting. We exited our holdings in DP Eurasia over increasing concerns about the Russian, and in particular, Turkish economies. Our stake in Philippine Seven was exited over concerns about the competitive environment. Medlive was exited as we became increasingly concerned over competition in the market in which it operates and the increasing divergence between its actual performance and what we thought it was capable of at the time of investment. The fund sold two Indian holdings in the period - Proctor & Gamble Hygiene and Eris, the former on valuation grounds, the latter over concerns about competition in the Indian generic pharmaceutical market. The top 5 contributors in the month were Hypera, Vitasoy, Mercadolibre, Genpact and Wal-Mart de Mexico. The top 5 detractors were Foshan Haitian, NetEase, Asian Paints, Tencent and Hindustan Unilever.

Top 10 holdings

Our Values

Asian Paints

No Fees For Performance

Mercadolibre

No Upfront Fees

Avenue Supermarts

No Nonsense

Nestlé India

No Debt or Derivatives

Hindustan Unilever

No Shorting

Hypera

No Market Timing

WNS

No

Index Hugging

Marico

No Trading

Foshan Haitian

No Hedging

Info Edge

Fundsmith knows

Factsheet

Performance chart

24/06/2014 - 31/10/2022

Cumulative performance (%) Performance data as at 31 October 2022

Key

Instrument

YTD

1M

3M

6M

1Y

3Y

5Y

From inception

From inception annualised

A

Fundsmith Emerging Equities Trust (NAV)

-13.1

-5.4

-2.4

-4.6

-13.0

3.3

14.9

32.9

3.5

B

Fundsmith Emerging Equities Trust (Price)

-11.0

-9.3

4.7

3.0

-13.8

3.9

7.8

22.3

2.4

C

Sector: Emerging Markets

-10.2

-5.2

-3.2

-6.9

-10.7

7.9

2.0

26.6

2.9

The OCF (Ongoing Charges Figure) is the total expenses paid by the fund (excluding bank overdraft interest), annualised, against its average net asset value. The OCF will fluctuate as the average net assets and costs change. The OCF is updated following the publication of accounts for the periods ending 30th June and 31st December.

Cash in the Sector and Geographic split represents current assets, of which cash is typically the largest part, less any current liabilities.

  • Estimated Portfolio Yield is an estimate of the dividends received as a percentage of the market capitalisation. Where the OCF exceeds the amount no dividends will be distributable to shareholders.
  • The PTR (Portfolio Turnover Rate) is a measure of the fund's trading activity, and has been calculated by taking the total share purchases and sales less total creations and liquidations divided by the average net asset value of the fund.

MSCI Emerging & Frontier Markets Index is the exclusive property of MSCI Inc. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or final products. This report is not approved, reviewed or produced by MSCI. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's and "GICS®" is a service mark of MSCI and Standard & Poor's.

Fundsmith LLP ("Fundsmith") is authorised and regulated by the Financial Conduct Authority and only acts for the funds to whom it provides regulated investment management and transaction arrangement services. Fundsmith does not act for or advise potential investors in connection with acquiring shares in Fundsmith Emerging Equities Trust plc and will not be responsible to potential investors for providing them with protections afforded to clients of Fundsmith. Prospective investors are strongly advised to take their own legal, investment and tax advice from independent suitably qualified advisers. The value of investments may go up as well as down. Past performance is not a guide to future performance.

  • 2022 Fundsmith LLP. All rights reserved. Fundsmith LLP is authorised and regulated by the Financial Conduct Authority. It is entered on the Financial Conduct Authority's register under registered number 523102. Fundsmith LLP is a limited liability partnership registered in England and Wales with number OC354233. Its registered office address is 33 Cavendish Square, London, W1G 0PW.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Fundsmith Emerging Equities Trust plc published this content on 02 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 November 2022 12:44:02 UTC.